<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693702</url>
  </required_header>
  <id_info>
    <org_study_id>Retro2</org_study_id>
    <nct_id>NCT04693702</nct_id>
  </id_info>
  <brief_title>Observational Study of Vision Improvement in Patients With Retinal Disorders</brief_title>
  <official_title>Observational Study of Vision Improvement in Patients With Retinal Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optimal Acuity Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optimal Acuity Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the vision improvement achieved by patients with&#xD;
      retinal disorders who received corneal treatments by a low vision aid device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the vision improvement achieved by patients with&#xD;
      retinal disorders, including age-related macular degeneration and diabetic macular edema, who&#xD;
      received corneal treatments by a low vision aid device. Patient records will be analyzed to&#xD;
      determine measures of vision improvement including best spectacle-corrected distance visual&#xD;
      acuity (CDVA). Analyses will include descriptive statistics and correlation between outcomes&#xD;
      and baseline characteristics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>CDVA</measure>
    <time_frame>12 months</time_frame>
    <description>Best spectacle-corrected distance visual acuity</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Age-related Macular Degeneration</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic Macular Edema</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Corneal treatment by a low vision aid device</intervention_name>
    <description>Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.</description>
    <arm_group_label>Age-related Macular Degeneration</arm_group_label>
    <arm_group_label>Diabetic Macular Edema</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with vision impairment due to retinal disorders involving central vision loss&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. - Female or male&#xD;
&#xD;
          2. - Any race&#xD;
&#xD;
          3. - Patient is at least 50 years old&#xD;
&#xD;
          4. - Patient has diagnosed retinal disorder that causes central vision loss in one or&#xD;
             both eyes&#xD;
&#xD;
          5. - Treated eyes, at time of treatment, were pseudophakic or phakic with no significant&#xD;
             vision loss due to cataract&#xD;
&#xD;
          6. - Patient had moderate to severe baseline vision impairment with CDVA of 20/63 or&#xD;
             worse (decimal = 0.317 or less; logMAR greater than or equal to 0.50) in the treated&#xD;
             eye(s)&#xD;
&#xD;
          7. - Patient CDVA records are available at baseline and at 1m or longer post-Tx times&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1 - Corneal disease or disorder in either eye 2 - Increased intraocular pressure (above&#xD;
        20mm Hg), glaucoma or history of glaucoma 3 - Presence or history of any other condition or&#xD;
        finding that, in the opinion of the investigator, makes the patient unsuitable for&#xD;
        retrospective observational study&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Berry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Optimal Acuity Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael J Berry, PhD</last_name>
    <phone>831-869-1384</phone>
    <email>mberry177@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raymond M Stein, MD</last_name>
    <phone>416-AMD-1000</phone>
    <email>raymondmstein@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bochner Eye Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R 1A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bochner Eye Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R 1A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Raymond M Stein, MD</last_name>
      <phone>416-AMD-1000</phone>
      <email>raymondmstein@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 31, 2020</study_first_submitted>
  <study_first_submitted_qc>December 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Diabetic macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

